Lisa M. Bell

Health Technology

Consumer Services

Profile

Lisa M.
Bell worked as a Senior Director-Regulatory & Safety at Abbott Biotherapeutics Corp.
and as the Head-Regulatory & Pharmacovigilance at BioMarin Pharmaceutical, Inc. She was also the Senior Vice President- Global Regulatory Affairs at Coherus BioSciences, Inc. from 2014 to 2017.
Bell received her undergraduate and graduate degrees from Boston University and her doctorate from the University of California, Berkeley.

Former positions of Lisa M. Bell

Companies	Position	End
COHERUS BIOSCIENCES, INC.	General Counsel	01/12/2017
Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	General Counsel	-
BIOMARIN PHARMACEUTICAL INC.	General Counsel	-

See the detail of Lisa M. Bell's experience

Training of Lisa M. Bell

University of California, Berkeley	Doctorate Degree
Boston University	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Lisa M. Bell's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
COHERUS BIOSCIENCES, INC.	Health Technology
BIOMARIN PHARMACEUTICAL INC.	Health Technology

Private companies	1
Abbott Biotherapeutics Corp. Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.	Health Technology